Active Ingredient History

  • Now
Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.   Wikipedia

  • SMILES: O=S(=O)(c1ccccc1)c2cnc3c(cccc3c2)N4CCNCC4
  • Mol. Mass: 353.45
  • ALogP: 2.48
  • ChEMBL Molecule:
More Chemistry
3-benzenesulfonyl-8-piperazin-1-ylquinoline | gsk742457 | gsk-742457 | intepirdine | rvt-101 | sb742457 | sb 742457 | sb-742457


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue